Trials / Terminated
TerminatedNCT00537511
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
A Multicenter, Phase I/IIA, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose and To Evaluate the Safety Profile of CC-4047 Administered in Combination With Cisplatin and Etoposide in Patients With Extensive Disease Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pomalidomide | |
| DRUG | Cisplatin | |
| DRUG | Etoposide |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2010-11-01
- Completion
- 2010-12-01
- First posted
- 2007-10-01
- Last updated
- 2019-11-19
- Results posted
- 2013-04-17
Locations
6 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00537511. Inclusion in this directory is not an endorsement.